Home » Market News » DirectorsTalk Highlights » A view from the hVIVO/Open Orphan Laboratory – Professor John Oxford
Open Orphan PLC

A view from the hVIVO/Open Orphan Laboratory – Professor John Oxford

With Marie’s help and encouragement from the scientific group and Cathal Friel, I am re starting “My View” Series which will be as before, a mixture of Science and with a personal view. Marie is very important, not least since she can read my writing after a 5-year absence. I am pleased to be back. I am Chairing the Scientific Advisory Group (SAG), and I am of drawing up a list of the good and famous! We (SAG) will meet once per year.

Actually during today so far there are two initiatives which pleased me. Firstly, I can see the initiative in the 2000 bed Nightingale Hospital in East London. In the Great Pandemic of 1918, which killed 250,000 young people in the UK a Prize possession was not a doctor but a nurse. Quiet nursing saved many lives at home where otherwise most people died. There were more beds in 1919 than today around 180,000 but most were occupied by wounded soldiers. There were no antibiotics, but oxygen and masks were used for intensive patients. On my next round Robin, I will discuss antivirals/vaccines.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.